Bevacizumab local complications.
Gordon-Angelozzi
Maximiliano
M
Velez-Montoya
Raul
R
Fromow-Guerra
Jans
J
García-Aguirre
Gerardo
G
Guerrero-Naranjo
Jose Luis
JL
Quiroz-Mercado
Hugo
H
Morales-Cantón
Virgilio
V
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage / Q000009:adverse effects*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D020256:Choroidal Neovascularization / Q000188:drug therapy; D003930:Diabetic Retinopathy / Q000188:drug therapy; D005128:Eye Diseases / Q000139:chemically induced* / Q000175:diagnosis; D005260:Female; D005451:Fluorescein Angiography; D006801:Humans; D007267:Injections; D008268:Macular Degeneration / Q000188:drug therapy; D008269:Macular Edema / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D014463:Ultrasonography; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014822:Vitreous Body; D055815:Young Adult
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab